Hoth Therapeutics
HOTH
About: Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
Employees: 3
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1% more capital invested
Capital invested by funds: $304K [Q1] → $307K (+$2.82K) [Q2]
0.33% less ownership
Funds ownership: 2.31% [Q1] → 1.99% (-0.33%) [Q2]
12% less funds holding
Funds holding: 17 [Q1] → 15 (-2) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
D. Boral Capital
Jason Kolbert
|
$5
|
Buy
Maintained
|
18 Aug 2025 |
Financial journalist opinion
Based on 4 articles about HOTH published over the past 30 days
